Phuturdex › Diseases › Paramyxoviridae Infections
Drugs in development · updated 30 October 2026
Paramyxoviridae Infections: drugs in development
As of 30 October 2026 there are 2 active clinical trials (recruiting or ongoing, phases I–III) on 4 drugs for paramyxoviridae Infections. 4 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DAS181 | III | 1 | NCT03808922 |
| SCB-1019T | I–II | 1 | NCT06984094 |
| SCB-1022 | I–II | 1 | NCT06984094 |
| SCB-1033 | I–II | 1 | NCT06984094 |
Sorted by most advanced phase and number of active trials.
All 4 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Respiratory syncytial virus infectious disease 12 drugs
- Respiration disorder 6 drugs
- Autoimmune disease 94 drugs
- Heart disease 17 drugs
- Virus Diseases 26 drugs
Broader categories
- Infection 71 drugs
- Virus Diseases 26 drugs
- RNA virus infectious disease 8 drugs
- Lung disease 104 drugs
- Respiratory disease 57 drugs
- Respiratory tract infection 46 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D018184 “Paramyxoviridae Infections”.